Clinical Trial Update: Arsenic Trioxide and Imatinib Mesylate in Treating Patients With Accelerated Phase or Blastic Phase Chronic Myelogenous Leukemia or Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia [Phase 1, Phase 2]

View source ↗

Summary

A completed Phase 1/2 trial evaluated arsenic trioxide in combination with imatinib mesylate for patients with accelerated-phase or blast-phase chronic myeloid …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Chronic Myeloid Leukemia
• Philadelphia Chromosome-positive Acute Lymphoblastic Leukemia

Drugs mentioned

• Gleevec (Imatinib)
• Trisenox (arsenic trioxide)

Snippet

Sponsor: Memorial Sloan Kettering Cancer Center | Conditions: Leukemia | Phase 1, Phase 2 | Status: COMPLETED